Acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature

Simple item page
dc.catalogadorgrr
dc.contributor.authorAbbott, Molly G.
dc.contributor.authorAllawi, Zahra
dc.contributor.authorHofer, Monika
dc.contributor.authorAnsorge, Olaf
dc.contributor.authorBrady, Stefen
dc.contributor.authorFadic Ruiz, Ricardo
dc.contributor.authorTorres Riveros, Gustavo Andres
dc.contributor.authorKnight, Ravi
dc.contributor.authorCalvo, Margarita
dc.contributor.authorBennett, David L. H.
dc.contributor.authorThemistocleous, Andreas C.
dc.date.accessioned2024-06-04T14:53:15Z
dc.date.available2024-06-04T14:53:15Z
dc.date.issued2022
dc.description.abstractSmall fiber neuropathy usually presents with gradual and progressive chronic length-dependent pain. Acute small fiber neuropathy is rarely reported. Three patients with acute onset neuropathic pain after Oxford-AstraZeneca ChAdOx1-S vaccination are described. Two patients were identified at the Oxford University NHS Foundation Trust, Oxford, UK and one patient in Red de Salud UC Christus, Santiago, Chile. All patients underwent a clinical assessment that included a detailed neurological examination, laboratory investigations, nerve conduction studies, thermal threshold testing, and skin biopsy for intra-epidermal nerve fiber density. Patients seen in Oxford underwent MRI of the brain and spinal cord. Cerebrospinal analysis was not performed. Neuropathic symptoms (burning pain, dysaesthesias) developed in the hands and feet within 2 weeks of vaccination. On clinical examination, there was pinprick and thermal hyposensitivity in the area of neuropathic pain. Laboratory investigation, nerve conduction tests, sympathetic skin responses, and MRI showed no relevant abnormalities. Thermal thresholds were abnormal and intra-epidermal nerve fiber density in the lower leg was reduced. In two cases symptoms persist after several months. Three cases of definite acute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination are described. At follow up, neuropathic pain was present in two of the patients.
dc.fechaingreso.objetodigital2024-06-04
dc.format.extent5 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1111/jns.12509
dc.identifier.eissn1529-8027
dc.identifier.issn1085-9489
dc.identifier.pubmedid35962630
dc.identifier.scopusidSCOPUS_ID:2-s2.0-85136891043
dc.identifier.urihttp://doi.org/10.1111/jns.12509
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86384
dc.identifier.wosidWOS:000847089700001
dc.information.autorucEscuela de Medicina; Fadic Ruiz, Ricardo ; 0000-0001-7050-5133; 51912
dc.information.autorucEscuela de Medicina; Torres Riveros, Gustavo Andres; 0000-0002-8582-4839; 1014385
dc.language.isoen
dc.nota.accesocontenido completo
dc.pagina.final329
dc.pagina.inicio325
dc.revistaJournal of the Peripheral Nervous System
dc.rightsacceso abierto
dc.rights.license CC BY 4.0 DEED Atribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/deed.en
dc.subjectCOVID-19 vaccination
dc.subjectNeuropathic pain
dc.subjectPeripheral neuropathy
dc.subjectSmall fibre neuropathy
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAcute small fiber neuropathy after Oxford-AstraZeneca ChAdOx1-S vaccination: A report of three cases and review of the literature
dc.typeartículo de revisión
sipa.codpersvinculados51912
sipa.codpersvinculados1014385
sipa.trazabilidadWOS;2022-10-11
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
J Peripheral Nervous Sys - 2022 - Abbott - Acute small fiber neuropathy after Oxford‐AstraZeneca ChAdOx1‐S vaccination A.pdf
Size:
535.18 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas